Skip to main content

Table 3 Interview respondents’ views on motivation for patient segmentation

From: Personalized medicine in Europe: not yet personal enough?

Benefits Experts
Avoiding side effects/optimize side effect profile Academics (3), clinical experts (2), economic experts (3), EFPIA representative (1), patient representatives (2)
Avoiding waste of resources/over-treating/selecting only patients who need it Academic (1), clinical experts (2), economic experts (3), EFPIA representative (1), patient representatives (2), payer (1)
Improved outcomes in terms of effectiveness/efficacy Academic (1), clinical expert (1), economic experts (3), patient representative (1), payer (1)
Better outcome/benefit/response rate (not specified) Academic (1), clinical experts (2), economic experts (2), provider (1)
Improved cost-effectiveness/value for money Clinical expert (1), economic experts (3), payer (1)
Reduce costs Economic experts (3), payer (1)
Improved length of life Academic (1), clinical expert (1), economic expert (1)
Improved quality of life Academic (1), economic expert (1)
Free-up time from clinicians Patient representative (1), payer (1)
  1. EFPIA, the European Federation of Pharmaceutical Industries and Associations